Cost Effectiveness of Azithromycin Versus Cefuroxime, with/without Erythromycin, in Hospitalized Patients with Community Acquired Pneumonia.

The purpose of this report is to assess the cost-effectiveness of azithromycin monotherapy for hospitalized patients with community acquired pneumonia against the current practice of a second generation cephalosporin withwithout erythromycin. A pharmacoeconomic analysis from the hospital perspective was performed on 266 evaluable patients from a multicenter clinical trial which was conducted from 1993-1995. No significant differences in clinical success or adverse events rates were detected. Health care resource utilization was extracted from the data base were transformedconverted to national costs. A sensitivity analysis was performed and statistics applied to the cost-effectiveness ratios.